DATA GRAPHICS | Data Byte
Biosimilar pegfilgrastims saved Medicare $500M in 2021
Part B pegfilgrastim spending fell from $1.4B in 2017 to $866M in 2021, with usage largely unchanged
March 7, 2023 12:16 AM UTC
Newly released data from CMS’s Part B spending dashboard show that use of biosimilar versions of Neulasta saved Medicare about $500 million in 2021, demonstrating the ability of biosimilars to cut healthcare costs.
Neulasta pegfilgrastim, which was developed by Amgen Inc. (NASDAQ:AMGN) and first approved in 2002, is a leukocyte growth factor indicated to decrease the incidence of infection in patients receiving myelosuppressive cancer drugs. ...